Discovery will assist treatment and research into fatal brain disorder

Research using newly developed Magnetic Resonance Imaging technology could soon allow clinicians to confirm Huntington's disease before symptoms appear in people who have the gene for the fatal brain disease.

An early confirmation of Huntington's disease in people who have tested gene positive for the disease could enable treatment to commence early, even before motor, cognitive and psychiatric symptoms arise.

Using Diffusion Magnetic Resonance Imaging (dMR), researchers from the Howard Florey Institute and Monash University in Melbourne have identified extensive white matter degeneration in patients recently diagnosed with Huntington's disease.

White matter forms the connections between brain regions, allowing one region to communicate with another. A breakdown of these structural connections in the brain could help to explain the complex motor and cognitive problems experienced by Huntington's disease patients in the early stages of the disease.

Scientists have recently shown that this white matter degeneration starts before patients are officially diagnosed however, the extent of white matter degeneration in Huntington's disease was previously unknown.

The early symptoms of Huntington's disease can be easily missed, as they are usually minor problems such as clumsiness, memory loss and loss of cognitive function.

These symptoms gradually become more severe over the years, inevitably leading to death within 15 to 20 years of diagnosis.

Working on this research was Florey PhD student Ms India Bohanna, who said this discovery could also assist in the future testing of new therapeutic strategies to treat the disease.

"Currently, the effectiveness of any new treatment is determined by its ability to reduce symptoms, but we know that changes in the brain occur a long time before symptoms arise," Ms Bohanna said

"Our discovery could allow researchers to test therapies even before symptoms appear.

"Not only does this research tell us more about how the brain degenerates early in Huntington's disease, but it also opens up new avenues in drug research and development.

Co-principal investigator, A/Prof Nellie Georgiou-Karistianis from Monash University explained, "By using diffusion MR to examine white matter degeneration early on, we can now test the ability of new therapeutics that may possibly reverse underlying degeneration in brain connections, which ultimately leads to the development of symptoms.

"Although there isn't yet a cure for Huntington's, researchers at the Florey and Monash, and from around the world are working to develop new treatments to delay the onset and severity of this devastating disease," A/Prof Georgiou-Karistianis said.

Collaborating on this project was the Florey's A/Prof Anthony Hannan, who has shown that mental and physical exercise can delay the onset of Huntington's disease and slow the progression of symptoms in a mouse model of the disease.

This is the first study to look at white matter changes across the whole brain in Huntington's disease, and importantly, to study how the breakdown of connections between brain regions might lead to the widespread deficits found in Huntington's disease patients.

The researchers hope to conduct further dMR studies to examine white matter degeneration in people who have tested gene positive to Huntington's disease but are up to 10 years away from developing symptoms.

Huntington's disease is an inherited disease caused by a mutation in a single gene and is inherited by 50 percent of the offspring of patients. The disease usually appears around middle age but can start in childhood. Huntington's disease affects approximately 7 people per 100,000 of the population in Australia.

Diffusion Magnetic Resonance Imaging is a recently developed brain imaging technique that enables examination of the brain at a microstructural level and the mapping of white matter tracts by tracking the movement of water in the brain.

This research will be presented at the 14th Annual Meeting of the Organisation for Human Brain Mapping, which opened on 15 June in Melbourne. This conference, supported by the Howard Florey Institute, will see the world's neuroimaging experts share their latest research and develop new collaborations.

This research has also been accepted for publication in Brain Research Reviews.

Source: Research Australia

Related stories:

FDA approves first drug for Huntington's disease
The U.S. Food and Drug Administration today approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.
Researchers uncover mechanism of action of antibiotic able to reduce neuronal cell death in brain
Virginia Commonwealth University researchers have discovered how an antibiotic works to modulate the activity of a neurotransmitter that regulates brain functions, which eventually could lead to therapies to treat Alzheimer’s disease, Huntington’s disease, epilepsy, stroke, dementia and malignant gliomas.
Physical activity delays onset of Huntington's in mouse model
The simple act of running in an exercise wheel delays the onset of some symptoms of Huntington’s disease in a mouse model of the fatal human disorder according to research published in the open-access journal BMC Neuroscience. These findings add insights into the pathogenesis of the disease and suggest possible preventive therapeutic targets.
Promising new drug targets identified for Huntington's disease
Research funded by the Wellcome Trust has provided a number of promising new drug targets for Huntington's disease, a neurodegenerative disease. Scientists at the University of Cambridge have identified a number of candidate drugs to investigate further which encourage cells to "eat" the malformed proteins that lead to the disease.
Increased level of magnetic iron oxides found in Alzheimer's disease
A team of scientists, led by Professor Jon Dobson, of Keele University in Staffordshire, UK, have found, for the first time, raised levels of magnetic iron oxides in the part of the brain affected by Alzheimer's Disease (AD).
US stands to lose a generation of young researchers
Five consecutive years of flat funding the budget of the National Institutes of Health (NIH) is deterring promising young researchers and threatening the future of Americans’ health, a group of seven preeminent academic research institutions warned today.
Rusty Worms in the Brain
Iron is vital to human life; for example, it is a component of hemoglobin, the substance that makes our blood red and supplies our cells with oxygen. However, iron can also cause heavy damage; it is thought that iron deposits in the brain contribute to certain forms of neurodegenerative diseases such as Parkinsons’s, Huntington’ s, and Alzhiemer’s.
Mental and physical exercise delays dementia in fatal genetic disease
Scientists at Melbourne’s Howard Florey Institute have discovered that mental and physical stimulation delays the onset of dementia in the fatal genetic disease, Huntington's disease.

News discussion:

Medicine & Health news